Discover trends, market shifts, and competitive outlooks for the transthyretin amyloidosis treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Anticipated CAGR of the Transthyretin Amyloidosis Treatment Market, and What Factors Will Drive It?
In recent times, the market size for transthyretin amyloidosis treatment has significantly expanded. The market is projected to rise from $5.52 billion in 2024 to an estimated $5.95 billion in 2025, with a compound annual growth rate of 7.8%. The substantial growth during the historic period is credited to factors like raised awareness about the disease, improvements in diagnostic equipment, the development and authorization of drugs, patient advocacy and assistance, and cooperative research.
The market size for treating transthyretin amyloidosis is predicted to witness significant upliftment in the forthcoming years, projected to reach a notable $8.04 billion by 2029, with a CAGR of 7.8%. The forecast period anticipates this growth due to factors like extensive therapeutic pipeline expansion, escalated genetic screening, worldwide campaigns for rare disease awareness, personalized treatment methodologies, and better treatment accessibility. Key trends expected to transpire in this period encompass the rise of combination therapies, strategic alliances for medication formulation, attention towards peripheral and cardiac manifestations, execution of patient education initiatives, and the inclusion of real-world proof in treatment protocols.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13129&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Transthyretin Amyloidosis Treatment Market?
Increased funding for research and development activities is anticipated to boost the transthyretin amyloidosis treatment market’s expansion. The funding dedicated to these activities is typically directed towards the advancement of scientific understanding, tech innovation, product creation, and process improvement. With more resources being poured into research and development, breakthroughs in treating transthyretin amyloidosis like the development of unique drugs, gene treatments, and precision medicine strategies are more feasible. These advancements offer patients a wider range of effective and personalized treatment options. To exemplify, in December 2022, Alnylam Pharmaceuticals, a US biopharmaceutical firm developing Vutrisiran for the treatment of ATTR amyloidosis, augmented its research and development investment from $792,156 in 2021 to $883,015 in 2022, marking an 11.49% increase. As such, these rising investments in research and development are set to propel the transthyretin amyloidosis treatment market’s growth. As the world’s population ages, the transthyretin amyloidosis treatment market is predicted to experience significant growth. This demographic shift, characterized by a higher median age due to declining fertility and increasing lifespan, brings with it a higher risk of transthyretin amyloidosis (ATTR). With more people getting older, there’s an increase in the number of Transthyretin Amyloidosis cases, resulting in a larger patient pool requiring treatment. For example, the World Health Organization reported in October 2022 that every country is seeing an expansion in the number and percentage of elderly individuals, predicting that by 2030, nearly one in every six people will be over 60 years old. Hence, the growing aging population is a major factor driving the growth of the transthyretin amyloidosis treatment market.
Which Primary Segments of the Transthyretin Amyloidosis Treatment Market Are Driving Growth and Industry Transformations?
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN): Early-Stage ATTR-PN, Advanced-Stage ATTR-PN
2) By Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Mild ATTR-CM, Moderate ATTR-CM, Severe ATTR-CM
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13129&type=smp
Which Regions Are Key Players in the Growth of the Transthyretin Amyloidosis Treatment Market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Most Significant Market Trends in the Transthyretin Amyloidosis Treatment Market?
Leading businesses in the transthyretin amyloidosis treatment market prioritize the creation of unique and advanced treatments like orphan drugs to improve patient results and broaden the range of treatments. Eplontersen, a specific orphan drug created to address transthyretin amyloidosis, often enjoys regulatory advantages that facilitate its development. For instance, in March 2023, Ionis Pharmaceuticals, Inc., a biotechnology research firm from Canada, had its new drug application for Eplontersen, a trial orphan drug for familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy, approved by The Food and Drug Administration (FDA). Eplontersen, designed to curb the production of transthyretin (TTR) protein, addresses both genetic and non-genetic variants of ATTR amyloidosis (amyloid transthyretin amyloidosis). Eplontersen was accorded orphan drug status by the FDA in 2022.
View the full report here:
What Parameters Are Used to Define the Transthyretin Amyloidosis Treatment Market?
Transthyretin amyloidosis is a slowly progressive condition characterized by the buildup of abnormal protein deposits in the body’s organs and tissues. Transthyretin amyloidosis treatment refers to the medical interventions and therapeutic strategies designed to manage and mitigate the effects of transthyretin amyloidosis (ATTR).
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13129
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
